Cynata Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Other Revenue	1.71	1.89	2.32	1.65	7.77
Revenue	1.71	1.89	2.32	1.65	7.77
Revenue Growth	-9.21%	-18.59%	39.98%	-78.71%	402.60%
Gross Profit	1.71	1.89	2.32	1.65	7.77
Selling, General & Admin	1.85	2.07	1.93	1.65	1.92
Research & Development	5.38	7.4	8.68	12.39	8.82
Amortization of Goodwill & Intangibles	0.26	0.28	0.28	0.28	0.28
Other Operating Expenses	1.91	1.49	1.42	1.89	1.78
Operating Expenses	9.53	11.5	12.55	16.54	13.84
Operating Income	-7.82	-9.61	-10.23	-14.89	-6.07
Interest & Investment Income	0.08	0.23	0.42	0.35	0.06
Currency Exchange Gain (Loss)	-	-0.01	0.07	0.26	0.56
EBT Excluding Unusual Items	-7.74	-9.39	-9.74	-14.28	-5.45
Asset Writedown	-1.35	-	-	-	-
Pretax Income	-9.09	-9.39	-9.74	-14.28	-5.45
Net Income	-9.09	-9.39	-9.74	-14.28	-5.45
Net Income to Common	-9.09	-9.39	-9.74	-14.28	-5.45
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	237	205	180	145	143
Shares Outstanding (Diluted)	237	205	180	145	143
Shares Change	15.49%	14.09%	23.80%	1.27%	9.85%
EPS (Basic)	-0.04	-0.05	-0.05	-0.10	-0.04
EPS (Diluted)	-0.04	-0.05	-0.05	-0.10	-0.04
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-456.59%	-509.82%	-441.78%	-899.97%	-78.09%
Profit Margin	-531.03%	-498.14%	-420.82%	-863.05%	-70.08%
EBITDA	-7.55	-9.33	-9.95	-14.61	-5.79
EBITDA Margin	-	-	-	-	-74.48%
D&A For EBITDA	0.26	0.28	0.28	0.28	0.28
EBIT	-7.82	-9.61	-10.23	-14.89	-6.07
EBIT Margin	-	-	-	-	-78.09%
Revenue as Reported	1.79	2.11	2.73	2.01	7.84